酪氨酸磷酸酶调控ALK阳性间变性大细胞淋巴瘤对ALK抑制剂耐药
该研究通过基因组功能缺失筛选发现PTPN1和PTPN2磷酸酶是ALK阳性间变性大细胞淋巴瘤对ALK酪氨酸激酶抑制剂耐药的关键驱动因子。机制上,PTPN1/PTPN2缺失通过过度激活SHP2、MAPK和JAK/STAT通路介导克唑替尼耐药,而联用SHP2抑制剂可协同抑制肿瘤生长并逆转耐药。
要点
- PTPN1或PTPN2缺失在体内外均诱导ALK阳性ALCL对ALK TKIs耐药。
- PTPN1/PTPN2缺失通过过度激活SHP2、MAPK和JAK/STAT通路介导克唑替尼耐药。
- 克唑替尼联合SHP2抑制剂可协同抑制敏感及耐药ALCL生长并逆转耐药。
核心结论
- PTPN1和PTPN2是调控ALK阳性ALCL对ALK TKIs敏感性的ALK磷酸酶,联合阻断SHP2可增强ALK抑制疗效。
研究设计与样本
- 研究采用基因组功能缺失筛选,结合体外和体内实验及患者样本RNA测序分析。
主要发现
- PTPN1或PTPN2缺失在体外和体内诱导对ALK TKIs耐药。
- PTPN1和PTPN2结合并调控ALK磷酸化及活性,致癌ALK和STAT3抑制PTPN1转录。
- PTPN1也是SHP2的磷酸酶,PTPN1/PTPN2缺失通过过度激活SHP2、MAPK和JAK/STAT通路介导克唑替尼耐药。
- 对ALK TKIs耐药的患者样本显示PTPN1和PTPN2下调伴SHP2表达上调。
- 克唑替尼联合SHP2抑制剂协同抑制野生型或PTPN1/PTPN2敲除ALCL生长并逆转TKI耐药。
临床怎么用
- 对于ALK阳性ALCL患者,可考虑克唑替尼联合SHP2抑制剂以增强疗效并克服耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anaplastic large cell lymphomas (ALCLs) frequently carry oncogenic fusions involving the anaplastic lymphoma kinase (ALK) gene. Targeting ALK using tyrosine kinase inhibitors (TKIs) is a therapeutic option in cases relapsed after chemotherapy, but TKI resistance may develop. By applying genomic loss-of-function screens, we identified PTPN1 and PTPN2 phosphatases as consistent top hits driving resistance to ALK TKIs in ALK+ ALCL. Loss of either PTPN1 or PTPN2 induced resistance to ALK TKIs in vitro and in vivo. Mechanistically, we demonstrated that PTPN1 and PTPN2 are phosphatases that bind to and regulate ALK phosphorylation and activity. In turn, oncogenic ALK and STAT3 repress PTPN1 transcription. We found that PTPN1 is also a phosphatase for SHP2, a key mediator of oncogenic ALK signaling. Downstream signaling analysis showed that deletion of PTPN1 or PTPN2 induces resistance to crizotinib by hyperactivating SHP2, the MAPK, and JAK/STAT pathways. RNA sequencing of patient samples that developed resistance to ALK TKIs showed downregulation of PTPN1 and PTPN2 associated with upregulation of SHP2 expression. Combination of crizotinib with a SHP2 inhibitor synergistically inhibited the growth of wild-type or PTPN1/PTPN2 knock-out ALCL, where it reverted TKI resistance. Thus, we identified PTPN1 and PTPN2 as ALK phosphatases that control sensitivity to ALK TKIs in ALCL and demonstrated that a combined blockade of SHP2 potentiates the efficacy of ALK inhibition in TKI-sensitive and -resistant ALK+ ALCL.
引用
- Karaca Atabay E, Mecca C, Wang Q, et al. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood. 2022. PMID: 34657149. doi:10.1182/blood.2020008136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。